Copyright
©The Author(s) 2018.
World J Gastroenterol. Mar 21, 2018; 24(11): 1196-1205
Published online Mar 21, 2018. doi: 10.3748/wjg.v24.i11.1196
Published online Mar 21, 2018. doi: 10.3748/wjg.v24.i11.1196
Table 4 Characteristics of the patients -nucleotide-binding oligomerization domain 2 status, classification and activity of the disease, C-reactive protein and vitamin D levels, and medication at the time of the study
No. | Sex | Age | NOD2 | Montreal classification | CDAI | CRP (mg/L) | Vitamin D (nmol/L) | Prednisolon (> 10 mg/d) | Azathio-prine | Anti-TNF-α |
1 | M | 24 | WT1 | A2 L3 L4 B1 | 121 | 2.58 | 104.0 | Yes | No | Yes |
2 | M | 28 | WT1 | A2 L3 B3p | 46 | < 1.0 | 62.9 | No | No | Yes |
3 | M | 64 | WT1 | A3 L3 B2p | 111 | 4.58 | 27.0 | Yes | No | Yes |
4 | F | 60 | WT | A2 L3 B2 | 100 | 2.27 | 72.5 | No | No | Yes |
5 | F | 62 | WT | A3 L3 B3p | 82 | < 1.0 | 58.2 | Yes | Yes | Yes |
6 | M | 46 | WT | A2 L3 L4 B2p | 110 | 4.97 | 32.9 | No | No | Yes |
7 | M | 38 | HO | A2 L3 B3p | 92 | 13.30 | 40.2 | No | Yes | No |
8 | M | 64 | HO | A3 L3 B1 | 34 | < 1.0 | 53.0 | No | No | Yes |
9 | F | 48 | HO2 | A2 L3 B2 | 54 | < 1.0 | 67.6 | No | No | Yes |
10 | M | 54 | HO | A2 L3 B2p | 103 | 1.63 | 51.9 | No | Yes | No |
11 | M | 26 | HO | A1 L3 B2p | 120 | 7.86 | 31.0 | No | Yes | Yes |
12 | M | 27 | HT | A2 L3 B1 | 106 | 1.41 | 47.2 | No | No | Yes |
13 | M | 37 | HT | A2 L3 B2p | 166 | 4.56 | 37.9 | No | Yes | No |
14 | F | 48 | HT | A2 L1 B3p | 115 | 1.01 | 55.2 | No | Yes | Yes |
15 | M | 57 | HT | A1 L3 B2p | 132 | 12.30 | 52.3 | No | No | Yes |
16 | M | 47 | HT | A2 L3 B3 | 60 | 2.62 | 92.0 | No | Yes | No |
- Citation: Schäffler H, Rohde M, Rohde S, Huth A, Gittel N, Hollborn H, Koczan D, Glass Ä, Lamprecht G, Jaster R. NOD2- and disease-specific gene expression profiles of peripheral blood mononuclear cells from Crohn’s disease patients. World J Gastroenterol 2018; 24(11): 1196-1205
- URL: https://www.wjgnet.com/1007-9327/full/v24/i11/1196.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i11.1196